Monograph Details
|
|
Immune System
> Immunization
|
|
TYPHIM Vi |
| Manufacturer |
|
Sanofi Pasteur, Inc. |
| Legal Classification |
|
Rx
|
| Generic Name |
|
Typhoid vaccine cell; surface purified Vi polysaccharide 25micrograms per 0.5mL; soln; for IM inj; contains phenol. |
| Indications |
|
Immunization against typhoid fever. |
| Children |
|
≥2yrs: 0.5mL in deltoid or vastus lateralis. |
| Adults |
|
Give at least 2 weeks before expected exposure; may repeat every 2 years. Adults: 0.5mL IM once in deltoid. |
| Contraindications |
|
Not for use in chronic carriers or patients with active infection. |
| Precautions |
|
Have epinephrine (1:1000) inj available. Immunocompromised states. Previous typhoid vaccination. Thrombocytopenia. Coagulopathies. Acute infection. Active febrile illness. Exposure to contaminated food and water should be avoided. Pregnancy (Cat.C). Nursing mothers. |
| Adverse Reactions |
|
Local reactions, malaise, headache, GI upset, myalgia, fever. |
| How Supplied |
Syringe (0.5mL)—1
Multidose vials—contact manufacturer |
| Additional Resources |
|
• Related Prescribing Note |
|
|
|
|
